July 29, 2024 05:52 AM EDT
R&D

Anavex’s new analy­sis of its Alzheimer’s pill shows mixed re­sults

Ryan Cross

Senior Science Correspondent

PHILADEL­PHIA — Twen­ty months ago, the small biotech com­pa­ny Anavex an­nounced that an ex­per­i­men­tal pill for Alzheimer’s dis­ease helped slow cog­ni­tive de­cline on three com­mon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times